Archive
Archive for the ‘XBI’ Category
The Opportunities In Health Care and Biotechnology ETFs Could Be Dramatic
March was the 10th anniversary of the beginning of the “tech wreck” when the NASDAQ peaked at 5132 on March 10, 2000. As we look back ten years and all that has transpired in technology and Read more…
These Biotech ETFs Gain Access To A Broader Array Of Biotech Companies
“Last week a number of biotech players, including Millipore (MIL), OSI Pharmaceuticals (OSIP), Intermune (ITMN) and Sequenom (SQNM) turned in double-digit gains in the volatile health care Read more…
Wednesday March 3rd ETF Movers: TAN, XBI
In midday trading Wednesday, the Claymore/MAC Global Solar Energy Index ETF (TAN) is outperforming other ETFs, up about Read more…
Biotech ETFs May Be Poised For A Great Year Ahead
“World stock indexes have struggled to continue the rally that began in 2009. Investors have begun to question the validity of the rally. However, there are small pockets of strength Read more…
How To Use ETFs To Profit From The Bubble Of All Bubbles
James Altucher, managing partner of Formula Capital, says we are setting the stage for another bubble. James notes that the stimulus has barely hit yet (less than 10% spent) and the economy is probably already stabilizing. He poses the question Read more…
Place Your Bets On Health Care Reform With These ETF’s (XBI, IBB)
Health Care Reform provides an opportunity with ETF’s as the Obama administration pushes to change the way the healthcare industry does business. It’s not a matter of “IF” but a matter of “When” Health Care Reform takes place. You can use ETF’s to profit from the agenda. Read more…
A Cure For Cancer? Look At This Biotech ETF (XBI)
Tom Dyson from istockanalyst.com reports that “Since 1983, the biotech sector as a whole has seen four triple-digit rallies… and even one quadruple-digit rally. That’s just for the whole sector. Some individual stocks went much higher. You see, investors love the promise of cancer cures and miracle drugs… so it’s easy for them to justify piling onto a rally.” Read more…
State Street to Rebalance Eight SPDR(R) Exchange Traded Funds In Accordance with New S&P Procedures
State Street Global Advisors (SSgA), the investment management arm of State Street Corporation (NYSE: STT), today announced it will rebalance the holdings of eight SPDR(R) exchange traded funds that seek to track S&P Select Industry Indices on June 19, 2009 in accordance with the new procedural changes implemented by Standard & Poor’s.
Beginning with the June 2009 rebalancing of the S&P Select Industry Indices, Standard & Poor’s will rebalance the indices to equal weights using closing prices on the second Friday of the rebalancing month (i.e. the stock price reference date is one week prior to the rebalancing date effective date). The rebalancing effective date will remain after the close of the third Friday of the month. Read more…
Stem Cell Index: YTD Analysis, Banking on NeoStem
The ETF Innovators Global Stem Cell and Regenerative Medicine Index tracks the performance of 40 stem cell and regenerative medicine companies on a global basis with market caps of less than $1 billion at the inception of the index. The total market value of the index will be tracked as a gauge of investor and trader sentiment toward stem cell companies from a starting value of 3,928 on 2/22/09.
The accompanying table includes statistics for the 40 companies in the ETF Innovators Global Stem Cell and Regenerative Medicine Index, which is down 10% at a composite market value of 3,533 from 3,928 at the index inception on 2/22/09. The index is down by 23.7% over the past year on an equal-weight basis, compared to losses of 24.5% for the Healthcare Sector SPDR (XLV), 16.2% for iShares Nasdaq Biotech (IBB), 18.5% for SPDR S&P Biotech (XBI), 28.5% for PowerShares Biotech & Genome (PBE), and 36.9% for the S&P 500 SPDR (SPY).
On a year-to-date basis (YTD), the stem cell index is up 28.8% on an equal-weight basis, thanks to major gains in many of the smallest companies in the index with the companies listed in the table in descending order by their YTD stock price changes. The stem cell index performance on a YTD basis compares favorably to losses of 9.1% for the Healthcare Sector SPDR (XLV), 6.8% for iShares Nasdaq Biotech (IBB), 13.5% for SPDR S&P Biotech (XBI), 6.6% for PowerShares Biotech & Genome (PBE), and 4.9% for the S&P 500 SPDR (SPY).
Integra LifeSciences (IART) regained its position as the market cap leader in the index at $634M since I last wrote about the index one month ago. Osiris Therapeutics (OSIR) has lost over one-third of its market value so far this year after halting a Phase 3 clinical trial in late March for what the Company termed a flawed trial design resulting in higher than expected placebo response rates. The most widely followed and traded proxy included in the index is StemCells (STEM), which has gained about 15% YTD and 8% over the past year.
One of the top 10 stock price gainers YTD (registering a gain of nearly 100%) is NeoStem (NBS), which is a leader in the pre-disease collection, processing and long-term storage of adult stem cells for future medical applications. Click here for a link to NeoStem’s five minute adult stem cell documentary video, which is hosted at their website.
Full Story: http://biomedreports.com/articles/most-popular/800-stem-cell-index-ytd-analysis-banking-on-neostem.html
Most Comments